VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
DGICA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
DGICADonegal Group Inc.
$18.83$690M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksDGICAFinancials

Donegal Group Inc. (DGICA) Financials

30Y historyFree accessUpdated daily

Revenue growth has decelerated to -3.7% in 2026Q1, while the combined ratio shows stabilization at 94.0% following a peak of 101.0% in 2023Q4.

DGICA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue969.21M978.01M989.61M927.34M848.22M816.47M777.82M812.16M769.13M737.4M687.34M635.11M585.3M544.2M510.45M472.99M408.82M386.26M372.31M340.62M329.97M319.85M287.79M214.99M203.8M185.16M170.58M159.71M130.59M121.33M117.6M
Revenue Growth %-2.46%-1.17%6.71%9.33%3.89%4.97%-4.23%5.59%4.3%7.28%8.22%8.51%7.55%6.61%7.92%15.7%5.84%3.75%9.3%3.23%3.16%11.14%33.86%5.49%10.07%8.55%6.81%22.3%7.63%3.17%15.75%
Medical Costs & Claims687.85M717.12M764.43M763.39M706.51M649.44M578.84M628.83M697.42M602.33M531.19M497.88M478.55M424.88M407.19M409.07M340.66M311.13M282.55M228.99M266.99M261.94M246.12M185.77M154.6M172.37M153.06M151.85M114.37M103.41M82.51M
Medical Cost Ratio %70.97%73.32%77.25%82.32%83.29%79.54%74.42%77.43%90.68%81.68%77.28%78.39%81.76%78.07%79.77%86.49%83.33%80.55%75.89%67.23%80.91%81.9%85.52%86.41%75.86%93.09%89.73%95.08%87.58%85.23%70.16%
Gross Profit281.35M260.9M225.18M163.95M141.71M167.02M198.98M183.33M71.71M135.07M156.14M137.23M106.76M119.32M103.26M63.92M68.15M75.13M89.76M111.63M62.98M57.91M41.67M29.22M49.2M12.79M17.52M7.86M16.22M17.92M35.09M
Gross Margin %29.03%26.68%22.75%17.68%16.71%20.46%25.58%22.57%9.32%18.32%22.72%21.61%18.24%21.93%20.23%13.51%16.67%19.45%24.11%32.77%19.09%18.1%14.48%13.59%24.14%6.91%10.27%4.92%12.42%14.77%29.84%
Gross Profit Growth %-15.86%37.35%15.69%-15.15%-16.06%8.54%155.64%-46.91%-13.5%13.78%28.54%-10.53%15.55%61.55%-6.21%-9.29%-16.29%-19.59%77.25%8.76%38.97%42.59%-40.61%284.66%-27%122.86%-51.51%-9.49%-48.94%11.42%
Operating Expenses200.8M163.31M162.84M158.88M145.35M136.68M135.71M126.24M119.95M122.96M114.82M109.64M90.47M86.61M75.41M70.66M58.31M54.46M57.67M58.78M6.36M5.56M4.61M3.79M32.71M5.7M5.78M4.23M4.54M3.74M-66.21M
OpEx / Revenue %20.72%16.7%16.45%17.13%17.14%16.74%17.45%15.54%15.6%16.67%16.7%17.26%15.46%15.92%14.77%14.94%14.26%14.1%15.49%17.26%1.93%1.74%1.6%1.76%16.05%3.08%3.39%2.65%3.48%3.08%-56.3%
Depreciation & Amortization2.06M3.08M3.87M4.33M4.84M5.84M6.72M5.57M6.61M6.11M6.59M6.74M3.52M3.05M3.95M4.11M3.14M2.55M2.4M2.45M2.71M3.07M2.47M1.53M1.24M1.13M982.93K936.37K520.67K400K300K
Combined Ratio %91.69%90.02%93.7%99.45%100.43%96.28%91.87%92.97%106.27%98.36%93.99%95.66%97.22%93.99%94.54%101.42%97.59%94.65%91.38%84.48%82.84%83.63%87.12%88.17%91.91%96.17%93.12%97.73%91.06%88.32%13.86%
Operating Income80.55M97.59M62.34M5.06M-3.64M30.34M63.27M57.08M-48.24M12.11M41.33M27.59M16.28M32.71M27.86M-6.74M9.84M20.68M32.09M52.85M56.62M52.35M37.05M25.44M16.49M7.09M11.74M3.63M11.68M14.17M101.3M
Operating Margin %8.31%9.98%6.3%0.55%-0.43%3.72%8.13%7.03%-6.27%1.64%6.01%4.34%2.78%6.01%5.46%-1.42%2.41%5.35%8.62%15.52%17.16%16.37%12.88%11.83%8.09%3.83%6.88%2.27%8.94%11.68%86.14%
Operating Income Growth %-56.55%1131.15%239.18%-111.99%-52.05%10.85%218.33%-498.18%-70.69%49.78%69.46%-50.22%17.42%513.37%-168.46%-52.39%-35.57%-39.28%-6.66%8.17%41.27%45.67%54.21%132.59%-39.61%223.58%-68.92%-17.61%-86.01%16.57%
EBITDA82.94M100.67M66.21M9.39M1.2M36.18M69.99M62.65M-41.63M18.22M47.92M34.33M19.81M35.76M31.81M-2.63M12.99M23.23M34.49M55.3M59.34M55.41M39.53M26.97M17.73M8.22M12.73M4.57M12.2M14.57M101.6M
EBITDA Margin %8.56%10.29%6.69%1.01%0.14%4.43%9%7.71%-5.41%2.47%6.97%5.41%3.38%6.57%6.23%-0.56%3.18%6.01%9.26%16.23%17.98%17.32%13.73%12.54%8.7%4.44%7.46%2.86%9.34%12.01%86.39%
Interest Expense1.35M1.35M946.02K619.81K620.56K895.61K1.2M1.58M2.3M1.59M1.66M1.11M1.52M1.64M2.36M2.13M799.58K1.75M1.82M2.88M2.8M2.27M1.61M1.29M1.12M2.25M3.29M1.54M1.3M900K400K
Non-Operating Income-1.35M-1.35M-946.02K-619.81K-620.56K-895.61K-1.2M-1.58M-2.3M-1.59M-1.66M-1.11M-1.52M-1.64M-2.36M-2.13M-799.58K-1.75M-1.82M-2.88M-2.8M-2.27M-1.61M-1.29M-1.12M-2.25M-3.29M-1.54M-1.3M-900K100.9M
Pretax Income80.56M97.59M62.34M5.06M-3.64M30.34M63.27M57.08M-48.24M12.11M41.33M27.59M16.28M32.71M27.86M-6.74M9.84M20.68M32.09M52.85M56.62M52.35M37.05M25.44M16.49M7.09M11.74M3.63M11.68M14.17M10.8M
Pretax Margin %8.31%9.98%6.3%0.55%-0.43%3.72%8.13%7.03%-6.27%1.64%6.01%4.34%2.78%6.01%5.46%-1.42%2.41%5.35%8.62%15.52%17.16%16.37%12.88%11.83%8.09%3.83%6.88%2.27%8.94%11.68%9.18%
Income Tax14.91M18.25M11.48M637.97K-1.68M5.08M10.46M9.93M-15.48M5M10.53M6.6M1.74M6.39M4.77M-7.19M-1.62M1.85M6.55M14.57M16.41M15.4M10.89M7.14M4.49M1.27M2.91M-3.03M2.66M3.53M2.2M
Effective Tax Rate %18.51%18.7%18.41%12.6%46.14%16.76%16.53%17.4%32.08%41.26%25.47%23.93%10.71%19.53%17.11%106.72%-16.49%8.93%20.41%27.57%28.98%29.41%29.38%28.08%27.23%17.96%24.75%-83.43%22.77%24.92%20.37%
Net Income65.65M79.34M50.86M4.43M-1.96M25.25M52.82M47.15M-32.76M7.12M30.8M20.99M14.54M26.32M23.09M452.95K11.47M18.83M25.54M38.28M40.21M36.95M31.61M18.29M12M5.82M8.84M6.66M9.02M10.64M8.6M
Net Margin %6.77%8.11%5.14%0.48%-0.23%3.09%6.79%5.81%-4.26%0.97%4.48%3.3%2.48%4.84%4.52%0.1%2.8%4.87%6.86%11.24%12.19%11.55%10.99%8.51%5.89%3.14%5.18%4.17%6.91%8.77%7.31%
Net Income Growth %-6.37%55.99%1049.3%325.86%-107.76%-52.18%12.01%243.93%-560.37%-76.9%46.74%44.37%-44.76%13.98%4998.24%-96.05%-39.1%-26.28%-33.28%-4.81%8.84%16.88%72.81%52.42%106.3%-34.16%32.75%-26.18%-15.26%23.73%-10.42%
EPS (Diluted)1.782.181.530.14-0.060.811.831.64-1.160.251.140.960.551.000.890.020.450.300.921.391.601.491.311.040.740.360.570.250.350.420.34
EPS Growth %-10.68%42.48%992.86%328.38%-107.57%-55.74%11.59%241.38%-564%-78.07%18.75%74.55%-45%12.36%4350%-95.56%50%-67.39%-33.81%-13.13%7.38%13.74%25.96%40.54%105.56%-36.84%128%-28.57%-16.67%23.53%-15%
EPS (Basic)-2.221.540.14-0.060.821.801.68-1.160.261.160.970.561.010.900.020.450.300.921.391.651.541.351.070.740.370.570.250.350.420.35
Diluted Shares Outstanding36.95M31.25M33.08M33.14M31.99M31.11M29.46M28.77M28.6M28.22M27.11M27.97M27.14M26.34M25.88M25.61M25.56M25.47M25.53M25.54M20M24.8M24.22M17.57M16.28M16.16M15.55M26.85M25.93M25.4M25.1M

Key Metrics

Growth RegimeContracting
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Regional Catastrophe Exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Facing Structural Headwinds

As reported in recent financial filings, Donegal Group's revenue growth has decelerated to -1.17% year-over-year, suggesting a strategic shift toward underwriting discipline or a potential loss of market share within the competitive Mid-Atlantic independent agency channel as the company navigates a challenging property and casualty pricing environment.

The transition from positive growth in 2024 to negative figures in early 2026 indicates that the company may be prioritizing rate adequacy over volume expansion. Investors should monitor whether this contraction reflects a deliberate exit from unprofitable segments or a broader inability to compete effectively in a hardening market.

Underwriting Profitability Remains Under Pressure

Based on the provided income statement data, the combined ratio has fluctuated significantly, reaching a peak of 101.0% in 2023Q4 before stabilizing near 94.0% in 2026Q1, which highlights the inherent volatility in the company's loss ratio and its ongoing sensitivity to inflationary pressures on claim settlement costs.

While the recent improvement in the combined ratio suggests better underwriting discipline, the historical volatility indicates that the company remains vulnerable to sudden spikes in loss severity. The reliance on the intercompany pooling agreement appears to be a critical factor in managing these margin swings, yet it does not fully insulate the firm from broader industry-wide cost inflation.

Operational Efficiency Through Shared Scale

According to the company's reported figures, the extremely low debt-to-equity ratio of 0.05% underscores a conservative capital structure that relies heavily on the intercompany pooling agreement with Donegal Mutual to maintain operational scale and solvency without the need for significant external debt financing or leverage.

This capital-light approach suggests that the company prioritizes long-term stability and A.M. Best ratings over aggressive balance sheet expansion. However, this reliance on the mutual affiliate may limit the company's strategic flexibility and could potentially prioritize policyholder interests over the returns expected by minority public shareholders.

Structural Risks in Pooling Arrangements

As indicated by the recent quarterly data, the company's reliance on the intercompany pooling agreement may mask underlying underwriting issues, as the net income volatility—ranging from a loss of $2.0M in 2023Q4 to a profit of $25.2M in 2025Q1—warrants further investigation into the sustainability of these earnings.

Investors should be cautious of the potential for reserve development to distort current period earnings, as the pooling structure can effectively smooth out performance at the expense of transparency. The lack of significant cash reserves relative to revenue suggests that any major catastrophe event could force a rapid and potentially dilutive capital call from the mutual affiliate.

DGICA — Frequently Asked Questions

Quick answers to the most common questions about buying DGICA stock.

What was Donegal Group Inc.'s (DGICA) revenue in 2025?

For fiscal year 2025, Donegal Group Inc. (DGICA) reported total revenue of $978.0M. This represents a 731.6% increase compared to $117.6M in 1996.

Is Donegal Group Inc. (DGICA) profitable?

Donegal Group Inc. (DGICA) is profitable, generating $79.3M in net income for the fiscal year ending 2025 with a net profit margin of 8.1%.

What is Donegal Group Inc.'s operating profit margin?

Donegal Group Inc. (DGICA) reported an operating income of $97.6M, resulting in an operating profit margin of 10.0%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Donegal Group Inc.'s gross profit and gross margin?

Donegal Group Inc. (DGICA) generated $260.9M in gross profit for the year, representing a gross profit margin of 26.7%. This demonstrates the company's core pricing power and production efficiency.